ロード中...
Targeting ALK in pediatric RMS does not induce antitumor activity in vivo
PURPOSE: The anaplastic lymphoma kinase (ALK) has been demonstrated to be a valid clinical target in diseases such as anaplastic large cell lymphoma and non-small cell lung cancer. Recent studies have indicated that ALK is overexpressed in pediatric rhabdomyosarcoma (RMS) and hence we hypothesized t...
保存先:
| 出版年: | Cancer Chemother Pharmacol |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6054567/ https://ncbi.nlm.nih.gov/pubmed/29855693 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-018-3615-7 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|